The clinical expression of hypertrophic cardiomyopathy (HCMP) has proved to be particularly heterogeneous with a diverse disease spectrum. 1)2) The end stage of HCMP, characterized by a left ventricular (LV) ejection fraction (EF) < 50% at rest, reflects global systolic dysfunction.
Introduction
received an echocardiography examination, and he was diagnosed with septal hypertrophied and non-obstructive HCMP (EF, 72%; septal thickness, 19.7 mm; posterior wall LV thickness, 10 mm; LV end-diastolic/systolic volume, 42.7/13.4 mL). Coronary angiography (CAG) showed a normal coronary artery. His mother had been diagnosed with apical hypertrophy, but there was no history of sudden death in any family member. He was discharged with beta-blocker.
The patient was hospitalized after 7 years because of syncope. Holter monitoring findings were infrequent ventricular premature contraction. A neurologic examination indicated normal results. Echocardiographic findings were non-obstructive HCMP with decreased LV wall thickness (16 mm) and low-normal EF values (EF = 63.9%). He was discharged with betablocker and angiotensin receptor blocker. The patient was rehospitalized 9 years later because of atypical chest discomfort. His blood pressure was 121/80 mm Hg, pulse rate was 77/min, and respiratory rate was 20/min. Echocardiography revealed akinesis at the basal to mid anteroseptal, basal to mid septal, A 58-year-old man had been diagnosed with non-obstructive hypertrophic cardiomyopathy (HCMP) according to echocardiography findings 16 years ago. Echocardiography showed ischemic cardiomyopathy (CMP)-like features with decreased systolic function but a non-dilated chamber. Coronary angiography was performed but showed a normal coronary artery. Cardiac magnetic resonance imaging (MRI) revealed multifocal transmural and subepicardial delayed-enhancing areas at the anteroseptal, septal, and inferoseptal left ventricular (LV) wall, and wall thinning and decreased motion of the anteroseptal LV wall. Findings of ischemic CMP-like features by echocardiography suggested microvascular dysfunction. This late stage of HCMP carries a high risk of sudden death. Cardiac MRI evaluation may be necessary in cases of ischemic CMP-like features in HCMP. In this case, the diagnosis of end-stage HCMP with microvascular dysfunction was confirmed by using cardiac MRI after a follow-up period of more than 16 years.
Findings of Cardiac Magnetic
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basal to mid inferior, and basal to mid anterior LV wall motion with decreased LV systolic function (EF = 45.5%) but normal chamber size (LV dimension diastole/systole, 54.8/42.3 mm) (Fig. 1) . A treadmill test revealed positive findings. Electrocardiographic changes showed horizontal ST depression > 2 mm on II, III, and aVF, and ST elevation on aVR and V1 during exercise. During the recovery phase, electrocardiography showed down-sloping ST depression and T wave inversions on II, III, and aVF.
To evaluate the underlying cause of the regional wall motion abnormality, CAG was performed but showed a normal coronary artery. Cardiac MRI revealed multifocal transmural and subepicardial delayed enhancing areas at the anteroseptal, septal and inferoseptal LV wall with wall thinning and decreased motion of the anteroseptal LV wall (Fig. 2) . Echocardiographic findings from several examinations during the follow-up period are shown in Table 1 . He was diagnosed with end-stage HCMP with microvascular dysfunction.
Discussion
HCMP is widely regarded as a disease predominantly associated with hyperdynamic LV systolic function in the absence of another cardiac or systemic disease (e.g., hypertension or aortic stenosis) capable of producing the magnitude of hypertrophy evident.
4) HCMP is not rare and is the most common genetic cardiovascular disease. 1) Remodeling of the LV chamber in HCMP has been shown to occur in several clinical circumstances, including progression of LV hypertrophy during adolescence.
5)
A small distinctive subset of HCMP patients (approximately 5-10%) show the evolution into the end stage (or "burned-out" phase), characterized by LV wall thinning, cavity enlargement and systolic dysfunction that resembles dilated CMP and produces a relentlessly progressive and irreversible heart failure.
1)6)
In 1998, Chang et al. 7) demonstrated two cases of HCMP progressing to dilated CMP-like features after a follow-up period of more than 15 years with echocardiographic evidence, but there was no cardiac MRI evaluation. Chang et al. 7) concluded that pathologic study of more cases is necessary to reveal the pathogenesis of the functional and morphological changes of the myocardium. In the previous study, end stage of HCMP among 44 cases was identified approximately after 14 ± 18 years. 3) This case that we encountered in 1999, diagnosed on echocardiography and CAG, had hypertrophied LV walls but a nondilated LV chamber. After a follow-up period of more than 16 years, echocardiographic findings from several examination were akinesis at the basal to mid anteroseptal, basal to mid septal, and basal to mid inferior, and basal to mid anterior LV wall motion with decreased LV systolic function (EF = 45%) but a normal chamber size. A treadmill test showed positive results. We considered the possibility of HCMP progressing to ischemic CMP-like features after a follow-up period of more than 16 years with echocardiographic evidence. However, the coronary artery was normal on CAG. Cardiac MRI revealed multifocal transmural and subepicardial delayed enhancing areas. Therefore, we diagnosed end stage of HCMP with fibrosis. However, it is unclear what progressed the end stage of HCMP by the cause of the pathologic mechanism. We consider that microvascular dysfunction is a common feature of HCMP and reflects the interplay of a variety of mechanisms, including reduced arteriolar density, fibrosis, and myocyte disarray. 8) Microvascular dysfunction promotes blunted myocardial blood flow, leading to recurrent myocardial ischemia, replacement fibrosis, and possibly adverse LV remodeling. 9) In patients with HCMP, the degree of microvascular dysfunction is a strong, independent predictor of clinical deterioration and death. 10) Similar to that observed in this patient, end-stage HCMP is an unfavorable complication with a mortality rate of 11% per year and a risk of sudden death.
3) Therefore, patients with marked disease progression and LV remodeling eventually become candidates for primary prevention of sudden death with implantable defibrillators and evaluation for heart transplantation.
2) Cardiac MRI evaluation may be necessary to guide these important treatment decisions. The reason cardiac MRI is essential is that it provides contrast visualization of late gadolinium enhancement (LGE), generally considered indicative of myocardial fibrosis.
11) Maron and Spirito 6) said that LGE, presumably representing the consequences of longstanding microvascular ischemia, and resulting in myocyte death and ultimately replacement fibrosis as a repair process, to be evident predominantly in thinner segment of LV and associated with abnormalities of wall motion. 12) There is also an inverse relationship between systolic function and LGE on cardiac MRI.
2)12) In patients with HCMP, a subset of patients with low-normal EF values (50-65%) are identified on contrast-enhanced cardiac MRI as having substantial degrees of LGE, suggesting a transition phase, potentially heralding the beginning of advanced LV remodeling and systolic dysfunction.
In conclusion, the present case demonstrated non-obstructive HCMP that progressed to ischemic CMP-like features diagnosed on echocardiography and cardiac MRI after a followup period of more than 16 years. This case was confirmed as the end stage of HCMP with fibrosis on cardiac MRI. Therefore, we may consider the end stage of HCMP in case of systolic and/or diastolic dysfunction with a variety of wall motion abnormality on echocardiography but normal coronary artery.
